Showing results (131-140 of 437) with videos related to
Sort By:
Pageof 44
Blood Cancer Discovery|November 15, 2021
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom MacroglobulinemiaAkhilesh Kaushal, Ajay K Nooka, Allison R Carr, et al.Cancer|June 22, 2010
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective studyJonathan L Kaufman, Ajay Nooka, Mark Vrana, et al.Cancers|October 13, 2021
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple MyelomaJames Ackley, Miguel Armenta Ochoa, Delta Ghoshal, et al.Clinical Lymphoma, Myeloma & Leukemia|July 29, 2023
Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple MyelomaSagar Lonial, Andrew D Bowser, Ajai Chari, et al.Cancer|February 7, 2018
Current developments in immunotherapy in the treatment of multiple myelomaMartin Köhler, Christine Greil, Michael Hudecek, et al.Immunologic Research|June 8, 2004
Reconstructing immunity after allogeneic transplantationCynthia R Giver, Jian-Ming Li, Mohammad S Hossain, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptorsEbenezer David, Rajni Sinha, Jing Chen, et al.British Journal of Haematology|July 23, 2011
Monoclonal antibodies in the treatment of multiple myelomaPaul G Richardson, Sagar Lonial, Andrzej J Jakubowiak, et al.Blood|August 25, 2005
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKTEbenezer David, Shi-Yong Sun, Edmund K Waller, et al.Pageof 44